• Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

  • Jun 16 2022
  • Durée: 2 min
  • Podcast

Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Écouter gratuitement

Voir les détails du balado

  • Résumé

  • EMPRISE is a 5-year monitoring program that uses Medicare and two commercial claims in the United States to assess the efficacy and safety of empagliflozin (EMPA). A total of 190,226 type 2 diabetes patients aged 18 years or older who started EMPA or a dipeptidyl peptidase-4 inhibitor (DPP-4i) and were followed for heart failure hospitalization in primary or any discharge position a composite of MI and stroke, and all-cause mortality (ACM). Safety outcomes were lower-limb amputations (LLA), non-vertebral fractures, diabetic ketoacidosis (DKA), acute kidney injury (AKI), renal and bladder cancers.

    EMPA was linked to a lower risk of hospitalization for heart failure, a similar risk of MI or stroke, and a lower risk of all-cause mortality when compared to DPP4i. EMPA was associated with lower risk of acute kidney injury, higher risk of diabetic ketoacidosis, and a similar risk of lower-limb amputations, fractures, and renal and bladder cancer.

    In conclusion, these findings back up EMPA's cardiovascular effectiveness in normal treatment, with a safety profile that matches recorded data.
    Voir plus Voir moins
Voir plus Voir moins
activate_Holiday_promo_in_buybox_DT_T2

Ce que les auditeurs disent de Effectiveness and Safety of Empagliflozin in Routine Care: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.

Évaluations sur Audible.ca

Évaluations sur Amazon.ca
Il n'y a pas encore de critiques pour ce titre.